Prof. Qingqing Cai 蔡清清
Chief Physician, Professor
Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of lymphoma and nasopharyngeal carcinoma. Hematopoietic stem cell transplantation and CAR-T cell therapy for lymphoma.
Dr. Cai is a Professor, Chief Physician, and doctoral supervisor at Sun Yat-sen University Cancer Center, and a Changjiang Scholar. Over the past five years, Dr. Cai published over 20 SCI papers as corresponding author in journals including Blood and Clinical Cancer Research. Dr. Cai leads five National Natural Science Foundation projects and a key Ministry of Science and Technology R&D project.
Professional roles
- Chair, Committee on Integrated Traditional Chinese and Western Medicine for Lymphoma, China Anti-Cancer Association
- Leader, Lymphoma Group, Oncology Branch, Guangdong Medical Association
- Chair, Lymphoma Committee, Guangdong Precision Medicine Application Association
- Vice Chair, Lymphoma Committee, China Health Care Association for the Elderly
Name order: in Chinese the family name comes first (Cai Qingqing). Papers usually list the name as Qingqing Cai or Cai Q.
Selected publications
131 papers on PubMed matched by name and affiliation; 50 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cancer Commun (Lond), 2026 (senior author): Erratum to "BRD2 induces drug resistance through activation of the RasGRP1/Ras/ERK signaling pathway in adult T-cell lymphoblastic lymphoma". PubMed 42978967
- Clin Cancer Res, 2026 (senior author): TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial. PubMed 42268339
- Chin Med J (Engl), 2026 (senior author): Long-term outcomes of vindesine or vincristine substitutions for vinblastine in classical Hodgkin lymphoma. PubMed 42637684
- Nat Commun, 2026 (senior author): Single-cell profiling of natural killer/T-cell lymphoma reveals stratified immune features and potential therapeutic implications. PubMed 42660902
- Biomark Res, 2026 (senior author): Mechanisms, optimization strategies, and salvage options for CAR-T cell therapy. PubMed 42681665
- Nat Commun, 2026 (senior author): Liposomal mitoxantrone plus tislelizumab in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma: a phase 1b/2 trial. PubMed 42297808
- Clin Cancer Res, 2026 (senior author): LM-101, an Anti-SIRPα Antibody, in Patients with Relapsed/Refractory Lymphoma and Advanced Head and Neck Cancer: An Open-Label, Multicenter, Phase I Trial. PubMed 41910591
- Nat Commun, 2026 (senior author): Zanubrutinib-rituximab followed by shortened chemoimmunotherapy as frontline treatment for mantle cell lymphoma (CHESS): a phase II trial. PubMed 41904192
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion